ArticleNature communications2023
Cultivation of marine bacteria of the SAR202 clade.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Functional dynamics and interactions within the bacterial community responsible for biodegradable plastic degradation during aerobic composting.Biodegradation · 2026Article
- Hi-C Links Reveal Viral Activity and Infection Within the Free-Living Microbial Community of a Secondary Chlorophyll Maximum in the Eastern Tropical North Pacific.Environmental microbiology · 2026Article
- A multilayered cell envelope of a member of the Chloroflexota offers an anchoring platform for the archaellum.Frontiers in microbiology · 2026Article
- Widespread deep-sea microorganisms in subseafloor geochemical cycling.Frontiers in microbiology · 2026Article
- Structure of a functional archaellum in Bacteria of the Chloroflexota phylum.Nature microbiology · 2025Article
- Article
- Diversity and composition of sponge-associated microbiomes from Korean sponges revealed by full-length 16S rRNA analysis.Scientific reports · 2025Article
- Genome-streamlined SAR202 bacteria are widely present and active in the euphotic ocean.The ISME journal · 2025Article
- Impact of growth conditions on the abundance and diversity of cultivable bacteria recovered fromFEMS microbes · 2025Article
- Leuconostoc aquikimchii sp. nov., a Lactic Acid Bacterium Isolated from Cabbage Watery Kimchi.Journal of microbiology (Seoul, Korea) · 2024Article
- Taxonomic and functional partitioning of Chloroflexota populations under ferruginous conditions at and below the sediment-water interface.FEMS microbiology ecology · 2024Article
- Deep metagenomic sequencing unveils novel SAR202 lineages and their vertical adaptation in the ocean.Communications biology · 2024Article
- Crystal structure of L-2-keto-3-deoxyfuconate 4-dehydrogenase reveals a unique binding mode as a α-furanosyl hemiketal of substrates.Scientific reports · 2024Article
- Unveiling the microbial diversity across the northern Ninety East Ridge in the Indian Ocean.Frontiers in microbiology · 2024Article
- A pilot study suggests the correspondence between SAR202 bacteria and dissolved organic matter in the late stage of a year-long microcosm incubation.Frontiers in microbiology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria of the SAR202 clade, within the phylum Chloroflexota, are ubiquitously distributed in the ocean but have not yet been cultivated in the lab. It has been proposed that ancient expansions of catabolic enzyme paralogs broadened the spectrum of organic compounds that SAR202 bacteria could oxidize, leading to transformations of the Earth's carbon cycle. Here, we report the successful cultivation of SAR202 bacteria from surface seawater using dilution-to-extinction culturing. The growth of these strains is very slow (0.18-0.24 day
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.